MET and cancer: To date, a number of radiopharmaceuticals (RPs) targeting the MET pathway, such as antibodies, peptides or small molecules, have been radiolabelled to detect the sites of various cancers ([64Cu]Cu-NOTA-rh-HGF, [89Zr]Zr-onartuzumab, [18F]F-AH113804, [11C]C-SU11274) (Luo et al. 2015; Jagoda et al. 2012; Arulappu et al. 2016; Wu et al. 2010), but there is currently no routine clinical use for them.